Clinical Trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 18, 2022 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced breast cancer.
Trial Details
NCT Number NCT05505812
Lead Sponsor The Affiliated Hospital of Qingdao University
Collaborators: Qingdao Sino-Cell Biomedicine Co., Ltd.
Conditions Breast Cancer
Enrollment 10 participants
Start Date 2022-10-08
Primary Completion 2023-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2022-08-18